Adriana Paladini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adriana Paladini has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Alfredo Pauciulo
Department of Neuroradiology, Vito Fazzi Hospital, Lecce, Italy
3 shared publications - Domenico Sergio Zimatore
Neuroradiologia, Azienda Ospedaliera Consordiale Policlinico di Bari, Bari, Italy
3 shared publications - Emilio Lozupone
Department of Neuroradiology, Vito Fazzi Hospital, Lecce, Italy
3 shared publications - Alessio Vitiello
Department of Neuroradiology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
2 shared publications - Daniele Giuseppe Romano
Department of Diagnostic and Interventional Neuroradiology, Ospedali Riuniti San Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
2 shared publications - Flavio Giordano
AORN Cardarelli Neuroradiologia, Napoli, Italy
2 shared publications
Latest Publications
- 8 June 2026
- Published by Wolters Kluwer Health in Neurosurgery
The Revolve Study: A Multicenter Registry Using the Flow Diverter Surpass Evolve® Device for the Endovascular Treatment of Intracranial Aneurysms
BACKGROUND AND OBJECTIVE: Flow diverter devices have revolutionized the treatment of intracranial aneurysms, but evidence on newer-generation devices remains limited. The Surpass Evolve (SE) was designed to improve deliverability and vessel wall apposition compared with its predecessors. This registry aimed to evaluate the feasibility, safety, and efficacy of SE in a large, real-world multicenter cohort with long-term follow-up. METHODS: Between May 2019 and December 2022, 275 consecutive aneurysms in 272 patients were treated with the SE flow diverter across 28 Italian centers. Clinical and imaging follow-up was completed by January 2024. Mid-term (≤6 months) and long-term (≤24 months) follow-ups, including clinical assessment, angiography, and cross-sectional imaging (computed tomography/magnetic resonance), were systematically collected and independently reviewed by a central Core Lab. RESULTS: The mean maximum diameter of the aneurysm was 11.2 mm, and the mean neck size was 5.4 mm. A total of 258 aneurysms were unruptured (93.8%), and 17 (6.2%) were ruptured. The majority arose from the anterior circulation (87.6%), with 12.4% in the posterior circulation. Device deployment was unsuccessful in 5/278 procedures (1.8%), and misdeployment occurred in 28/278 (10%). The overall device-related mortality was 0.7%, and the morbidity was 5.4%. At mid-term follow-up, complete or near-complete occlusion was achieved in 66% of aneurysms, increasing to 92% at long-term. According to mass criteria, 82% of aneurysms were considered cured, whereas sac enlargement occurred in 0.5% and 17% remained unchanged in volume. CONCLUSION: Our experience using SE for endovascular treatment of intracranial aneurysms showed a high safety and efficacy profile, substantially equivalent to that of the other flow diverter devices commonly used.
- 8 June 2026
- Published by Wolters Kluwer Health in Neurosurgery
The Revolve Study: A Multicenter Registry Using the Flow Diverter Surpass Evolve® Device for the Endovascular Treatment of Intracranial Aneurysms
BACKGROUND AND OBJECTIVE: Flow diverter devices have revolutionized the treatment of intracranial aneurysms, but evidence on newer-generation devices remains limited. The Surpass Evolve (SE) was designed to improve deliverability and vessel wall apposition compared with its predecessors. This registry aimed to evaluate the feasibility, safety, and efficacy of SE in a large, real-world multicenter cohort with long-term follow-up. METHODS: Between May 2019 and December 2022, 275 consecutive aneurysms in 272 patients were treated with the SE flow diverter across 28 Italian centers. Clinical and imaging follow-up was completed by January 2024. Mid-term (≤6 months) and long-term (≤24 months) follow-ups, including clinical assessment, angiography, and cross-sectional imaging (computed tomography/magnetic resonance), were systematically collected and independently reviewed by a central Core Lab. RESULTS: The mean maximum diameter of the aneurysm was 11.2 mm, and the mean neck size was 5.4 mm. A total of 258 aneurysms were unruptured (93.8%), and 17 (6.2%) were ruptured. The majority arose from the anterior circulation (87.6%), with 12.4% in the posterior circulation. Device deployment was unsuccessful in 5/278 procedures (1.8%), and misdeployment occurred in 28/278 (10%). The overall device-related mortality was 0.7%, and the morbidity was 5.4%. At mid-term follow-up, complete or near-complete occlusion was achieved in 66% of aneurysms, increasing to 92% at long-term. According to mass criteria, 82% of aneurysms were considered cured, whereas sac enlargement occurred in 0.5% and 17% remained unchanged in volume. CONCLUSION: Our experience using SE for endovascular treatment of intracranial aneurysms showed a high safety and efficacy profile, substantially equivalent to that of the other flow diverter devices commonly used.
- Open Access
- 9 February 2026
- Published by MDPI AG in Journal of Interdisciplinary Research Applied to Medicine
- Vol. 6 (1) , 4
A Physiological, Non-Cannulated CT–Dacryocystography Protocol Using Dropwise Iodixanol Instillation: A Pilot Study
Background: Conventional CT–dacryocystography (CT-DCG) requires canalicular cannulation and forced contrast injection, which may distort anatomy and cause discomfort. This study describes a non-cannulated CT-DCG protocol using dropwise iodixanol 320 instillation designed to simulate physiological tear drainage. Methods: We retrospectively reviewed 80 patients (25 males, 55 females; mean age 64.3 ± 8.9 years) with suspected nasolacrimal duct obstruction. Iodixanol 320 was instilled at 2 drops/min for 10 min without cannulation. Imaging was performed on a low-dose 128-slice CT system with multiplanar reconstructions. Lacrimal patency, obstruction site, and patient discomfort (10-point VAS) were evaluated by a blinded radiologist. Results: Adequate contrast opacification was achieved in all cases. Obstruction was detected in 70/80 (87.5%) patients. Mean patient discomfort was 2.1 ± 1.3 VAS scale, lower than the values reported in the literature for conventional CT-DCG. No adverse reactions occurred. Conclusions: Non-cannulated CT-DCG with dropwise iodixanol instillation is a feasible and well-tolerated imaging technique that provides high diagnostic yield while preserving physiological tear flow. Further prospective, comparative studies are warranted to validate these findings.
- 9 February 2026
- Published by MDPI AG in Journal of Interdisciplinary Research Applied to Medicine
- Vol. 6 (1) , 4
Open AccessA Physiological, Non-Cannulated CT–Dacryocystography Protocol Using Dropwise Iodixanol Instillation: A Pilot Study
Background: Conventional CT–dacryocystography (CT-DCG) requires canalicular cannulation and forced contrast injection, which may distort anatomy and cause discomfort. This study describes a non-cannulated CT-DCG protocol using dropwise iodixanol 320 instillation designed to simulate physiological tear drainage. Methods: We retrospectively reviewed 80 patients (25 males, 55 females; mean age 64.3 ± 8.9 years) with suspected nasolacrimal duct obstruction. Iodixanol 320 was instilled at 2 drops/min for 10 min without cannulation. Imaging was performed on a low-dose 128-slice CT system with multiplanar reconstructions. Lacrimal patency, obstruction site, and patient discomfort (10-point VAS) were evaluated by a blinded radiologist. Results: Adequate contrast opacification was achieved in all cases. Obstruction was detected in 70/80 (87.5%) patients. Mean patient discomfort was 2.1 ± 1.3 VAS scale, lower than the values reported in the literature for conventional CT-DCG. No adverse reactions occurred. Conclusions: Non-cannulated CT-DCG with dropwise iodixanol instillation is a feasible and well-tolerated imaging technique that provides high diagnostic yield while preserving physiological tear flow. Further prospective, comparative studies are warranted to validate these findings.
- 18 December 2025
- Published by Springer Nature in Neuroradiology
- Vol. 68 (4) , 1047-1056
Real-world use of the pEGASUS-HPC stent in cerebral aneurysms: results from a multicenter retrospective series
Background and purpose Stent-assisted coiling has revolutionized the treatment of wide-neck intracranial aneurysms. Several technical improvements have since emerged, including enhanced deliverability, low-profile designs, and reduced surface thrombogenicity. This study aimed to assess the real-world feasibility, safety, and efficacy of the pEGASUS-HPC device for intracranial aneurysms. Materials and methods This independent, multicenter, retrospective observational study evaluated patients treated with pEGASUS-HPC stent-assisted coiling between April 2022 and December 2024. Data on procedural outcomes, complications (technical and clinical), and imaging follow-up were analyzed. Results Ninety-nine aneurysms (30 ruptured (30.3%), 69 unruptured (69.7%)) in 98 patients (58 female (59.2%), 40 male (40.8%) were treated using 130 pEGASUS-HPC stents. The successful deployment rate was 97%. Device-related mortality and morbidity were 2% and 1%, respectively. Ischemic complication rates did not significantly differ between acute and elective cases or between single and dual antiplatelet therapy groups. Adequate occlusion (Raymond-Roy Class I–II) was achieved in 95% immediately post-procedure and 93% at follow-up (median 240 days). Conclusions The pEGASUS-HPC stent shows high feasibility, safety, and effectiveness in the treatment of intracranial aneurysms. Further research is warranted to assess the impact of its surface coating, especially in emergency settings.
- 18 December 2025
- Published by Springer Nature in Neuroradiology
- Vol. 68 (4) , 1047-1056
Real-world use of the pEGASUS-HPC stent in cerebral aneurysms: results from a multicenter retrospective series
Background and purpose Stent-assisted coiling has revolutionized the treatment of wide-neck intracranial aneurysms. Several technical improvements have since emerged, including enhanced deliverability, low-profile designs, and reduced surface thrombogenicity. This study aimed to assess the real-world feasibility, safety, and efficacy of the pEGASUS-HPC device for intracranial aneurysms. Materials and methods This independent, multicenter, retrospective observational study evaluated patients treated with pEGASUS-HPC stent-assisted coiling between April 2022 and December 2024. Data on procedural outcomes, complications (technical and clinical), and imaging follow-up were analyzed. Results Ninety-nine aneurysms (30 ruptured (30.3%), 69 unruptured (69.7%)) in 98 patients (58 female (59.2%), 40 male (40.8%) were treated using 130 pEGASUS-HPC stents. The successful deployment rate was 97%. Device-related mortality and morbidity were 2% and 1%, respectively. Ischemic complication rates did not significantly differ between acute and elective cases or between single and dual antiplatelet therapy groups. Adequate occlusion (Raymond-Roy Class I–II) was achieved in 95% immediately post-procedure and 93% at follow-up (median 240 days). Conclusions The pEGASUS-HPC stent shows high feasibility, safety, and effectiveness in the treatment of intracranial aneurysms. Further research is warranted to assess the impact of its surface coating, especially in emergency settings.
- Open Access
- 9 June 2025
- Published by SAGE Publications in Interventional Neuroradiology
The use of FD-HPC in Ruptured and Unruptured Aneurysms, the Italian Dataset (RUAID): Preliminary results on feasibility and safety
Background: The introduction of flow diverters (FDs) has revolutionized the treatment of complex intracranial aneurysms; subsequent surface modifications have extended their indications to ruptured, bifurcation, and distal aneurysms. The aim of this study is to assess the real-world feasibility and safety of HPC surface-modified devices in the treatment of ruptured and unruptured aneurysms. Methods: This independent, multicenter, prospective observational study evaluated the outcomes of patients treated with implanted Phenox p64 or p48 MW-HPC-FDs between 2020 and 2022. The sub-analysis of the procedures, complications (clinical and technical), and additional treatment requirements assessed the devices’ feasibility and safety in the peri-procedural period. Results: One hundred and forty aneurysms (35% ruptured and 65% unruptured) were treated in 140 patients (37 females and 103 males) using 153 HPC-FDs (111 p64 and 42 p48): 100 aneurysms were saccular (71%), 22 dissecting (16%), 13 fusiform (9%), and five blister-like (3.6%). The successful deployment rate was 97.9%. The overall peri-procedural mortality rate was 9%, including three device-related deaths (2.2%); the overall morbidity rate was 12.1% (6.4% severe, 3.6% mild, and 2.1% asymptomatic adverse events); 4.4% of the clinical adverse events were certainly device related, and 2.2% were probably device related. Conclusions: The use of p64 and p48 HPC-FDs is highly feasible and acceptably safe, although further data are needed to assess the impact of the coating on safety in emergency and elective procedures.
- 9 June 2025
- Published by SAGE Publications in Interventional Neuroradiology
Open AccessThe use of FD-HPC in Ruptured and Unruptured Aneurysms, the Italian Dataset (RUAID): Preliminary results on feasibility and safety
Background: The introduction of flow diverters (FDs) has revolutionized the treatment of complex intracranial aneurysms; subsequent surface modifications have extended their indications to ruptured, bifurcation, and distal aneurysms. The aim of this study is to assess the real-world feasibility and safety of HPC surface-modified devices in the treatment of ruptured and unruptured aneurysms. Methods: This independent, multicenter, prospective observational study evaluated the outcomes of patients treated with implanted Phenox p64 or p48 MW-HPC-FDs between 2020 and 2022. The sub-analysis of the procedures, complications (clinical and technical), and additional treatment requirements assessed the devices’ feasibility and safety in the peri-procedural period. Results: One hundred and forty aneurysms (35% ruptured and 65% unruptured) were treated in 140 patients (37 females and 103 males) using 153 HPC-FDs (111 p64 and 42 p48): 100 aneurysms were saccular (71%), 22 dissecting (16%), 13 fusiform (9%), and five blister-like (3.6%). The successful deployment rate was 97.9%. The overall peri-procedural mortality rate was 9%, including three device-related deaths (2.2%); the overall morbidity rate was 12.1% (6.4% severe, 3.6% mild, and 2.1% asymptomatic adverse events); 4.4% of the clinical adverse events were certainly device related, and 2.2% were probably device related. Conclusions: The use of p64 and p48 HPC-FDs is highly feasible and acceptably safe, although further data are needed to assess the impact of the coating on safety in emergency and elective procedures.
- Open Access
- 1 April 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (4) , 850-857
Mechanical Thrombectomy in Prestroke Disability: Data From the Italian Endovascular Stroke Registry
BACKGROUND: The benefits and safety of mechanical thrombectomy (MT) in patients with prestroke disability, classified as modified Rankin Scale (mRS) score of 3 to 4, and anterior circulation stroke remain uncertain. This study aims to evaluate these factors using data from the Italian Registry of Endovascular Treatment in Acute Stroke. METHODS: We analyzed data collected between 2015 and 2021, comparing functional outcomes (mRS), symptomatic intracerebral hemorrhage, and recanalization rates (Thrombolysis in Cerebral Infarction) at 90 days post-MT in patients with prestroke mRS score of 3 to 4 versus 0 to 2. A good outcome was defined as no change in the mRS score from baseline. Subgroup analysis was stratified by age. RESULTS: A total of 11.411 (96%) patients with prestroke mRS score of 0 to 2 and 477 (4%) patients with prestroke mRS score of 3 to 4 were included. Compared with patients with a baseline mRS score 0 to 2, those with mRS score 3 to 4 were older (82 versus 75 years; P P P =0.556). Mortality was significantly higher in the mRS score 3 to 4 group (n=159 [37.1%] versus n=1939 [18.4%]; P P =0.002), while no significant differences in symptomatic intracerebral hemorrhage were found. The benefit of MT was maintained in patients aged 80 to 85 and over 85 years with prestroke mRS score 3 to 4, although mortality remained higher. CONCLUSIONS: Our data suggest that prestroke disability does not imply less chance of returning to prestroke conditions after MT, even in octogenarians, despite higher mortality and lower recanalization rate. More data are warranted to better understand the benefit of MT in this subgroup of patients.
- 1 April 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (4) , 850-857
Open AccessMechanical Thrombectomy in Prestroke Disability: Data From the Italian Endovascular Stroke Registry
BACKGROUND: The benefits and safety of mechanical thrombectomy (MT) in patients with prestroke disability, classified as modified Rankin Scale (mRS) score of 3 to 4, and anterior circulation stroke remain uncertain. This study aims to evaluate these factors using data from the Italian Registry of Endovascular Treatment in Acute Stroke. METHODS: We analyzed data collected between 2015 and 2021, comparing functional outcomes (mRS), symptomatic intracerebral hemorrhage, and recanalization rates (Thrombolysis in Cerebral Infarction) at 90 days post-MT in patients with prestroke mRS score of 3 to 4 versus 0 to 2. A good outcome was defined as no change in the mRS score from baseline. Subgroup analysis was stratified by age. RESULTS: A total of 11.411 (96%) patients with prestroke mRS score of 0 to 2 and 477 (4%) patients with prestroke mRS score of 3 to 4 were included. Compared with patients with a baseline mRS score 0 to 2, those with mRS score 3 to 4 were older (82 versus 75 years; P P P =0.556). Mortality was significantly higher in the mRS score 3 to 4 group (n=159 [37.1%] versus n=1939 [18.4%]; P P =0.002), while no significant differences in symptomatic intracerebral hemorrhage were found. The benefit of MT was maintained in patients aged 80 to 85 and over 85 years with prestroke mRS score 3 to 4, although mortality remained higher. CONCLUSIONS: Our data suggest that prestroke disability does not imply less chance of returning to prestroke conditions after MT, even in octogenarians, despite higher mortality and lower recanalization rate. More data are warranted to better understand the benefit of MT in this subgroup of patients.